In contrast the co-stimulatory receptors (CD80, CD86) and CD83 are not influenced by the tumor, HLA-DR expression is even decreased in many cases and the early activation marker CD25 [30] is only presented by a small subpopulation [unpublished data]. This evidence concerns the gene CD86 and neoplasm.